- SEK40.57bn
- SEK36.61bn
- SEK2.27bn
Brief: EMA Says CHMP Recommends Refusal Of Marketing Authorisation For Lagevrio For COVID-19 In Adults
Brief: Camurus Sees Total Revenues For 2023 In Range Of SEK 1,530-1,650 Mln
Brief: Camurus Sees 2023 Revenues Rising to SEK 1530-1650 Million
Brief: Camurus Withdraws Variation Application For CAM2038 To Include Chronic Pain
Brief: Camurus Says PDUFA Action Date for Brixadi NDA for Treatment of Opioid Use Disorder In US Set For 23 May 2023
Brief: Camurus Announces PDUFA Date For Brixadi NDA For The Treatment Of Opioid Use Disorder In The US
Brief: Camurus Announces Braeburn Resubmits NDA For Brixadi In The U.S.
Brief: Camurus Q3 Operating Result Turns To Profit Of SEK 41 Mln
Brief: Camurus Presents Five-Year Vision
Brief: Camurus Receives SEK 29.8 Mln Through Exercise Of Warrants
Brief: Camurus Q2 EBIT Turns To Profit At SEK 7 Million
Brief: Camurus Divests Episil Oral Liquid Business To Solasia
Brief: Camurus Q1 Operating Result Swings To Profit SEK 5 Million
Europe Research Roundup: Hexagon, Proximus, Sodexo
Brief: Camurus Q4 Operating Loss Narrows To SEK 18 Mln
Brief: Camurus AB Says Braeburn Receives New Complete Response Letter For Brixadi In The U.S.
Brief: Camurus Q3 Operating Loss Narrows To SEK 6 Mln
Brief: Camurus Names Jon U. Garay Alonso New CFO
Brief: FDA Grants Camurus Orphan Drug Designation For The Treatment Of Polycystic Liver Disease